Summary

Global Latent Tuberculosis Infection Detection Market is valued at approximately USD XX billion in 2021 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2022-2029. Latent Tuberculosis Infection (LTBI) is a variety of TB infection in which bacteria remains inactive specifically bacteria that exists in the sleeping state inside the individual’s body. The detection of this infection is identified by the tuberculin skin test (TST). The risk is increased by other diseases including drug abuse, HIV, or medications that weakens the immune system. Factors such as surging demand for tuberculosis testing, growing funding to manage disease treatment, and increasing geriatric population are driving the market growth globally.

The rising risk of developing active TB from latent tuberculosis infection (LTBI) is propelling the demand for market across the globe. According to TBFacts.org, in 2021, about 40% of Indians are estimated to be infected with the TB bacteria, with the great majority having latent TB instead of active TB disease. Likewise, according to the Centers for Disease Control and Prevention report 2021, it was estimated that up to 13 million people in the United States suffered from latent TB infection. Therefore, the high prevalence rate of latent tuberculosis infection among the population is augmenting the market growth. Furthermore, growing awareness campaigns conducted by non-government bodies and market players, as well as a rising number of government initiatives to treat LTBI are leveraging multiple opportunities in the foreseen years. However, the lack of a systematic approach to screening tuberculosis and the unavailability of proper recommendations and reimbursement policies are hindering market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Latent Tuberculosis Infection Detection Market study include Asia Pacific, North America, Europe, Latin America, and the Rest of the World. North America dominated the market in terms of revenue, owing to the growing awareness about early diagnosis of infection, high funding for tuberculosis management, and improvement of healthcare facilities. Whereas, Asia Pacific is expected to grow at the highest CAGR during the forecast period. Factors such as high infection rates in developing countries, increasing population, as well as government favorable initiatives are burgeoning the market growth in the forecasting years.

Major market players included in this report are:
QIAGEN N.V.
Oxford Immunotec Inc.
F. Hoffmann-La Roche Ltd.
Sanofi S.A.
Abbott Laboratories
bioMérieux SA
Becton, Dickinson, and Company
Endo International plc
PerkinElmer, Inc.
Bruker Corporation
Recent Developments in the Market:
 In February 2022, QIAGEN N.V. announced that the company received approval for its QuantiFERON tuberculosis testing solution in China. With this strategic initiative company aims to boost its market share across the region.





Global Latent Tuberculosis Infection Detection Market Report Scope:
Historical Data 2019-2020-2021
Base Year for Estimation 2021
Forecast period 2022-2029
Report Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered Test Type, End-User, Region
Regional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World
Customization Scope Free report customization (equivalent up to 8 analyst’s working hours) with purchase. Addition or alteration to country, regional & segment scope*





The objective of the study is to define the market sizes of different segments & countries in recent years and to forecast the values for the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within the countries involved in the study.

The report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with a detailed analysis of the competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Test Type:
Tuberculin Skin Test
Interferon Gamma Release Assays

By End User:
Diagnostic Laboratories
Hospitals/Clinics
Academic & Research Institutions

By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
ROLA
Rest of the World

ページTOPに戻る

Table of Contents

Chapter 1. Executive Summary
1.1. Market Snapshot
1.2. Global & Segmental Market Estimates & Forecasts, 2019-2029 (USD Billion)
1.2.1. Latent Tuberculosis Infection Detection Market, by Region, 2019-2029 (USD Billion)
1.2.2. Latent Tuberculosis Infection Detection Market, by Test Type, 2019-2029 (USD Billion)
1.2.3. Latent Tuberculosis Infection Detection Market, by End-User, 2019-2029 (USD Billion)
1.3. Key Trends
1.4. Estimation Methodology
1.5. Research Assumption
Chapter 2. Global Latent Tuberculosis Infection Detection Market Definition and Scope
2.1. Objective of the Study
2.2. Market Definition & Scope
2.2.1. Scope of the Study
2.2.2. Industry Evolution
2.3. Years Considered for the Study
2.4. Currency Conversion Rates
Chapter 3. Global Latent Tuberculosis Infection Detection Market Dynamics
3.1. Latent Tuberculosis Infection Detection Market Impact Analysis (2019-2029)
3.1.1. Market Drivers
3.1.1.1. Rising risk of developing active TB from latent tuberculosis infection (LTBI)
3.1.1.2. Surging demand for tuberculosis testing
3.1.2. Market Challenges
3.1.2.1. Lack of a systematic approach to screening tuberculosis
3.1.2.2. Unavailability of proper recommendations and reimbursement policies
3.1.3. Market Opportunities
3.1.3.1. Growing awareness campaigns conducted by non-government bodies and market players
3.1.3.2. Rising number of government initiatives to treat LTBI
Chapter 4. Global Latent Tuberculosis Infection Detection Market Industry Analysis
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.2. Futuristic Approach to Porter’s 5 Force Model (2019-2029)
4.3. PEST Analysis
4.3.1. Political
4.3.2. Economical
4.3.3. Social
4.3.4. Technological

4.4. Top investment opportunity
4.5. Top winning strategies
4.6. Industry Experts Prospective
4.7. Analyst Recommendation & Conclusion
Chapter 5. Risk Assessment: COVID-19 Impact
5.1. Assessment of the overall impact of COVID-19 on the industry
5.2. Pre COVID-19 and post COVID-19 Market scenario
Chapter 6. Global Latent Tuberculosis Infection Detection Market, by Test Type
6.1. Market Snapshot
6.2. Global Latent Tuberculosis Infection Detection Market by Test Type, Performance - Potential Analysis
6.3. Global Latent Tuberculosis Infection Detection Market Estimates & Forecasts by Test Type 2019-2029 (USD Billion)
6.4. Latent Tuberculosis Infection Detection Market, Sub Segment Analysis
6.4.1. Tuberculin Skin Test
6.4.2. Interferon Gamma Release Assays
Chapter 7. Global Latent Tuberculosis Infection Detection Market, by End-User
7.1. Market Snapshot
7.2. Global Latent Tuberculosis Infection Detection Market by End-User, Performance - Potential Analysis
7.3. Global Latent Tuberculosis Infection Detection Market Estimates & Forecasts by End-User 2019-2029 (USD Billion)
7.4. Latent Tuberculosis Infection Detection Market, Sub Segment Analysis
7.4.1. Diagnostic Laboratories
7.4.2. Hospitals/Clinics
7.4.3. Academic & Research Institutions
Chapter 8. Global Latent Tuberculosis Infection Detection Market, Regional Analysis
8.1. Latent Tuberculosis Infection Detection Market, Regional Market Snapshot
8.2. North America Latent Tuberculosis Infection Detection Market
8.2.1. U.S. Latent Tuberculosis Infection Detection Market
8.2.1.1. Test Type breakdown estimates & forecasts, 2019-2029
8.2.1.2. End-User breakdown estimates & forecasts, 2019-2029
8.2.2. Canada Latent Tuberculosis Infection Detection Market
8.3. Europe Latent Tuberculosis Infection Detection Market Snapshot
8.3.1. U.K. Latent Tuberculosis Infection Detection Market
8.3.2. Germany Latent Tuberculosis Infection Detection Market
8.3.3. France Latent Tuberculosis Infection Detection Market
8.3.4. Spain Latent Tuberculosis Infection Detection Market
8.3.5. Italy Latent Tuberculosis Infection Detection Market
8.3.6. Rest of Europe Latent Tuberculosis Infection Detection Market
8.4. Asia-Pacific Latent Tuberculosis Infection Detection Market Snapshot
8.4.1. China Latent Tuberculosis Infection Detection Market
8.4.2. India Latent Tuberculosis Infection Detection Market
8.4.3. Japan Latent Tuberculosis Infection Detection Market
8.4.4. Australia Latent Tuberculosis Infection Detection Market
8.4.5. South Korea Latent Tuberculosis Infection Detection Market
8.4.6. Rest of Asia Pacific Latent Tuberculosis Infection Detection Market
8.5. Latin America Latent Tuberculosis Infection Detection Market Snapshot
8.5.1. Brazil Latent Tuberculosis Infection Detection Market
8.5.2. Mexico Latent Tuberculosis Infection Detection Market
8.5.3. Rest of Latin America Latent Tuberculosis Infection Detection Market
8.6. Rest of The World Latent Tuberculosis Infection Detection Market

Chapter 9. Competitive Intelligence
9.1. Top Market Strategies
9.2. Company Profiles
9.2.1. QIAGEN N.V.
9.2.1.1. Key Information
9.2.1.2. Overview
9.2.1.3. Financial (Subject to Data Availability)
9.2.1.4. Product Summary
9.2.1.5. Recent Developments
9.2.2. Oxford Immunotec Inc.
9.2.3. F. Hoffmann-La Roche Ltd.
9.2.4. Sanofi S.A.
9.2.5. Abbott Laboratories
9.2.6. bioMérieux SA
9.2.7. Becton, Dickinson, and Company
9.2.8. Endo International plc
9.2.9. PerkinElmer, Inc.
9.2.10. Bruker Corporation
Chapter 10. Research Process
10.1. Research Process
10.1.1. Data Mining
10.1.2. Analysis
10.1.3. Market Estimation
10.1.4. Validation
10.1.5. Publishing
10.2. Research Attributes
10.3. Research Assumption